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PERSPECTIVES IN RENAL MEDICINE
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Estimating prevalence in single-gene kidney diseases prog- (Table 1). In addition, DNA analysis disclosed locus
ressing to renal failure. Incidence and prevalence, the measures heterogeneity in a large number of them, meaning that
of “frequency,” are often confused. While in a nonhereditary mutations in either of two (or three) separately located
situation, the useful parameter is the incidence rate, evaluating
genes result in the same phenotype. In contrast with thesethe impact of an etiologic factor, it is prevalence that is consid-
precise data, it became apparent that our information onered useful in a hereditary disease. Prevalence may concern
the frequency of single-gene kidney diseases was far fromeither the whole population or a fraction of this population, that
is, males or females or individuals at a given age, for example, at complete. Individually, most of them, except for autoso-
birth. Pathologic phenotype and morbid genotype prevalences mal dominant polycystic kidney disease (ADPKD), are
have to be clearly differentiated. In this article, we review the rare. However, taken as a whole, their impact in terms
epidemiologic surveys allowing an estimation of the distribu-
of morbidity, hospitalizations, mortality, and cost to soci-tion of major single-gene kidney diseases progressing to renal
ety is high. The purpose of this article is to report andfailure in different populations. In order to compare their re-
discuss the descriptive epidemiologic studies measuringsults, the geographic/ethnic composition of the population, the
determination of its size, the choice and mode of calculation the distribution of major single-gene kidney diseases
of the epidemiologic measure, the definition of the disease progressing to end-stage renal disease (ESRD). These
and modes of diagnosis, the inclusion of cases, the sources of surveys may also allow an estimation of the frequency
ascertainment and the possible causes of underascertainment, of new mutations produced to replace the genes lost byand the period of time during which events were counted
natural selection, or the mutation rate.should be analyzed accurately. Although their impact in terms
of morbidity, hospitalizations, mortality, and cost to society is
high, this review shows that information on the prevalence of
MEASURES OF DISEASE FREQUENCYsingle-gene kidney diseases is far from complete. To date, the
data essentially apply to large populations of European origin. The basic measures
A part of the variation among prevalence data may be due to
To characterize the importance of a gene, of a geno-methodological differences. Not representative are the small
type, or of a phenotype (normal or pathologic) in a givenpopulations in which some rare diseases, especially recessive,
population, geneticists often use the term “frequency.”are found with a high prevalence.
This term is imprecise, however, when considering he-
reditary diseases. In this situation, in order to quantitate
morbidity, it is necessary to use measures traditionally
The last decade has shown increasing awareness of used by epidemiologists, that is, incidence and preva-
the problems encountered in diagnosis of single-gene lence [1]. Although these measures are defined differ-
kidney diseases. The use of molecular genetics in these ently, are estimated differently, have different units, and
diseases has culminated in the mapping of most genes have different ranges of possible values, they are often
confused [2]. The terms used in this review refer to the
definitions given below, even if the authors used a differ-
Key words: prevalence, polycystic kidney disease, Alport syndrome, ent term.
nail-patella syndrome, Finnish-type nephrotic syndrome, nephro-
Even today, ambiguities persist concerning the con-nophtisis, Bardet-Biedl syndrome, cystinosis, primary hyperoxaluria
type 1, Fabry disease, von Hippel-Lindau disease, tuberous sclerosis. cept of incidence and its measures [3]. The incidence
rate in a given population measures the number of newReceived for publication July 12, 1999
(or incident) cases of a disease occurring during a specificand in revised form April 7, 2000
Accepted for publication April 14, 2000 period. Three components are required: N, the number
of individuals at risk in the population; d, the numberÓ 2000 by the International Society of Nephrology
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Table 1. Major single-gene renal diseases progressing to end-stage renal disease
Inheritance Gene Chromosome
Structural disorders of the kidney
Autosomal dominant polycystic kidney disease (ADPKD) AD PKD1 16p
AD PDK2 4q
AD third gene? —
Autosomal recessive polycystic kidney disease (ARPKD) AR PKHD1 6p
Glomerular disorders
Alport syndrome (AS) XD COL4A5 Xq
AR COL4A3 2q
AR COL4A4 2q
Nail-patella syndrome (NPS) AD LMX1B 9q
Congenital nephrotic syndrome of Finnish type (CNF) AR NPHS1 19q
Tubular and tubulointerstitial disorders
Nephronophtisis (NPH1) AR NPHP1 2q
AR NPHP2 9q
Bardet-Biedl syndrome (BBS) AR BBS1 11q
AR BBS2 16q
AR BBS3 3p
AR BBS4 15q
AR BBS5 2q
Metabolic disorders
Cystinosis AR CTNS 17p
Primary hyperoxaluria type 1 (PH1) AR AGXT 2q
Fabry disease XR GLA Xq
Phakomatoses
Tuberous sclerosis (TSC) AD TSC1 9q
AD TSC2 16p
von Hippel-Lindau disease (VHL) AD VHL 3p
Abbreviations are: AD, autosomal dominant; AR, autosomal recessive; XD, X-linked dominant; XR, X-linked recessive.
of new cases; and t, the observation period during which The useful parameter is the incidence rate measuring
the impact of the etiologic factor. In hereditary diseases,every individual at risk of the disease is observed. The
the genotype (for example, mutation in the gene CFTR)
incidence rate is given by
d
Nt
. If the population is stable cause of the disease, and the phenotype (cystic fibrosis)
are two expressions of the same fact, even if the relation-and the disease is rare, the denominator (person-years)
ship between them is not complete in case of incompleteis the product of the number of years of observation by
penetrance. In this situation, incidence refers to the firstthe size of the population. Another measure of incidence
diagnostic episode in a person’s life, that is, conversionis the risk or probability of developing disease, also termed
of a normal to an abnormal phenotype. Considering such“cumulative incidence” by some but not all authors. It
a measure may be interesting in order to study the ge-is equivalent to the number of new cases of disease in
netic or environmental factors implicated in the age ata specified period of time divided by the number of indi-
onset of the pathologic phenotype, but the main measureviduals at the start of the observation period.
is prevalence. Prevalence may concern either the wholePrevalence measures the proportion of individuals in
population or a fraction of this population, that is, malesa population who have the disease of interest either at
or females or individuals at a given age, for example,a specific point or within a period of time. Two compo-
children or newborns. Often treated as an incidence mea-
nents are required: N, the number of individuals at risk sure, the proportion of birth defects, whether detected
in a population; and D, the number of individuals with at birth or not, is an example of prevalence measure
because it depends not only on the incidence of defectsthe disease. Prevalence is given by
D
N 1 D
. It does not
at conception or during embryogenesis, but also on the
differentiate between old and new cases. It is influenced prenatal survival of affected fetuses [1]. By analogy, the
by factors affecting the incidence of the disease and its proportion of children born with a pathologic phenotype
course, including treatment, survival, and cure. (for example, Down syndrome) or a metabolic abnormal-
It is important to outline the differences that exist in ity (for example, phenylalanine hydroxylase deficiency)
the relationship between etiologic factor and disease in in a population of newborns is considered a prevalence
nonhereditary diseases (the epidemiologic situation) and measure. Basically, birth prevalence is measured by the
in hereditary diseases (the genetic situation) [4]. In the number of children born with the genetic disease in a
first situation, the etiologic factor (for example, tobacco) given population divided by the total number of live
births in the corresponding time.and the disease (lung cancer) are different phenomena.
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Estimation of disease prevalence The prevalence date should be chosen to be sufficiently
remote from the time of the study to allow existing casesEstimation of disease prevalence involves the collec-
to be recognized and diagnosed, but not to have died andtion of all affected individuals over a specified period in
been forgotten [5]. This interval, obviously dependingthe target population. It requires the continuing coopera-
on the characteristics of each disease, should be discussedtion of professionals (experienced and dedicated workers
from the outset. In poorly known diseases [for example,or a small team based in the area, who have considerable
Fabry disease or nail-patella syndrome (NPS)], it maytenacity and determination) and often high financial costs.
take more than five years (or even more) for a diagnosisThe study design should obey several well-defined and
to be reached.carefully described rules so that reported surveys may
To detect index cases, as many separate sources of ascer-be compared. When applied to genetic diseases, the tra-
tainment should be used as possible. Each of the sourcesditional epidemiologic questions must, however, be mod-
(for example, registers, reports from hospitals, clinics,ified. Ethical problems, mostly linked to the specific ques-
private physicians, family doctors, genetic clinics, biol-tion of a genetic disease and differing from one country
ogy, radiology and histopathology laboratories, deathto another, should be considered from the outset.
certificates, and patient associations) may possibly yieldThe geographic area must be well defined [5]. It usually
corresponds to some administrative or political bound- information on patients not detected by means of the
ary. The area must be sufficiently large to avoid bias from other sources. Ad hoc registers with regular collection
large kindreds, but sufficiently small to allow complete of data constitute the best method of ascertainment [6].
coverage. Five hundred thousand to 5 million classically In contrast, other sources are structures that recruit cases
represent the outer limits for population size. However, without having an epidemiologic vocation. Most widely
in case of relatively rare conditions, a large population used are the population of a specific hospital or of a
needs to be surveyed. All parts of the area should ideally hospital unit or the experience of a number of hospitals,
be covered with equal thoroughness. Hence, access to most authors presuming that all patients are admitted
medical facilities and the health care system have to be to hospitals. Depending on the clinical presentation of
evaluated in the whole area. Only living cases resident the disease, various sources besides nephrology depart-
in the area on the prevalence dates are compared with ments (for example, urology departments, ophtalmologi-
the total population of the area at the same dates. cal clinics, and institutes for the mentally handicapped)
The demographic characterization of the denominator may be consulted. Furthermore, some information on
population should be based on official statistics. The num- the relative prevalence can be derived from the frequency
ber of individuals at risk is generally estimated through at which specific diagnoses (for example, lysosomal stor-
a national census, conducted once every 10 years. This age diseases and inborn errors of metabolisms) are made
may be a problem in developing countries where cen- by reference laboratories.
suses are infrequent or where significant undercounting When multiple sources of ascertainment are used, the
occurs. Moreover, because human populations are dy- identification of individuals is crucial. It should be re-
namic groups with individuals continuously joining or membered that medical files of patients are confidential.
leaving (deaths, births, and migration), intercensal esti-
In some countries, cross-checking may be forbidden bymates may be wrong. Some countries or regions that are
law, thus introducing sometimes serious limitations tocharacterized by a stable population with relatively little
the feasibility of the research.migration (for example, the department of Cotes d’Armor
Because of the variability of clinical expression ofin France and Wales in the United Kingdom) have been
each disorder, diagnostic criteria should be homogeneouschoice locations for epidemiologic surveys.
throughout the country (problem of numerous investiga-Accurate information on the age, sex, and if possible,
tors) and the period considered. The phenotypic classifi-ethnic characteristics of the population should be avail-
cation is heterogeneous, being based on the presence ofable so that appropriate denominators can be used. Data
clinical manifestations and/or laboratory tests. Ideally,specific to age (standard-age groups), sex, and ethnic
molecular DNA analysis in patients with minor symp-groups may be used. For diseases occurring in childhood,
toms or before the disease is clinically obvious wouldprevalence in the corresponding age group seems prefer-
eliminate misclassification. Its application to such studiesable to prevalence in the whole population. Because of
does not seem feasible. Correctness and firmness of diag-the severity in males, sex-specific data should be pro-
nosis have to be evaluated in all patients. This issue isvided in dominant X-linked diseases [for example, Al-
crucial for disorders with incomplete penetrance whereport syndrome (AS)].
the characteristic phenotype may not be expressed at allThe study should be continued over a considerable
in some individuals carrying the mutation.period of time [5]. Three years appears to be a minimum
Causes of underascertainment should not be ignored.study period, and five years is preferable. It has been
Complete ascertainment can never be proven, but argu-shown that a survey, if repeated after an interval, usually
produces a significant increase in prevalence. ments may support the assumption of an optimal sam-
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pling of all patients. Failures in reporting and/or underdi- them as likely or unlikely to have the disease. In any
case, a screening test(s) should be acceptable, cheap, andagnosis (for example, lack of reporting, incomplete
retrieval of hospital and office charts, inability to trace valid (for example, kidney ultrasonography in ADPKD).
The second design includes nonscreened asymptom-known patients, lack of response to postal inquiries, renal
condition omitted from death certificates, patients with atic heterozygotes. According to the expectations of au-
tosomal dominance, the risk of a person with an affectedmultiple problems, often the elderly, usually followed
by general physicians, and mild cases missing if only parent, sibling, or child being heterozygous is 50%, and
the risk of a person with an affected grandparent beinghospitals provide cases) result in underestimation of the
prevalence. heterozygous is 25%. Asymptomatic heterozygotes will
consequently be estimated by counting one half of thoseSeveral investigators claimed that any study deter-
mining disease frequency should incorporate a formal with 50% risk and one quarter of those with 25% risk
in complete pedigree structures obtained in each family.assessment of undercount [7]. In their opinion, the cap-
ture-recapture method, widely used in animal ecology Such a calculation using crude prior risk percentages
results in an overestimation of the number of heterozy-to estimate population size, is a means to obtain an
accurate evaluation of the nonascertained cases. Briefly, gotes. Different methods of correction, depending either
on age-at-onset distribution or age-related risk, previouslythis approach uses the number of cases found by a pri-
mary source and by a secondary source and the number established for the disease under study, have been rec-
ommended [5].of cases common to both. Using the source overlap infor-
mation, the total population can be estimated, and 95% Birth prevalence. Ideally, birth prevalence should be
evaluated from population-based newborn surveys orpercentage confidence intervals can be placed around
this estimate [8]. For other authors, the applications of from following a cohort of births in which the genetic
disease is ascertained at various ages. Official informa-the model are restrictive and, when applied to medical
conditions, are not usually met in practice [9]. First, the tion on the annual number of newborns is usually pro-
vided in each country.method requires independent sources for accurate esti-
mates. In human diseases, being on one list is often associ- If the disease is not apparent at or shortly after birth,
another means is to conduct a retrospective study allowingated with being on another. Second, there may be a
portion of false-positive cases among the subjects identi- calculation of the proportion of children with a given
disease born each year in a given population. In additionfied as having the disease. Calculating a standard devia-
tion for the estimation of missing cases does not solve the to renal diseases in which onset occurs in infancy [that is,
congenital nephrotic syndrome of Finnish type (CNF)],problem of underascertainment, and in their opinion,
the method cannot replace a direct population survey. such an indirect measurement appears valuable when on-
set occurs in early childhood [that is, autosomal recessiveAs shown by a recent exchange on tuberous sclerosis
(TSC), supporters of the capture-recapture method [10] polycystic kidney disease (ARPKD), X-linked AS in
males, nephronophtisis, cystinosis]. Ascertainment de-are opposed to supporters of direct population surveys
[11]. pends not only on the completeness of recognition of the
clinical phenotype and reporting, but also on the survivalOnce an index case(s) has been identified, complete
families should be carefully evaluated. Such an intensive (infants or children might die without the disease having
been diagnosed), on the length of the study period (chil-search requires sheer effort, and detective work is essen-
tial. Secondary symptomatic cases, some previously undi- dren having not yet presented typical signs are missed),
and on possible family departure before apparent onset.agnosed, others recognized but not previously ascertained
by the investigator, may be discovered [5]. As previously Finally, risk on the one hand and heterozygote fre-
quency on the other hand may be considered equivalentmentioned, ethical conduct may be a limitation to the
study, since it is necessary to obtain permission from of birth prevalence. When the whole life is considered
and if penetrance is complete, estimation of risk allowsindex patients to contact relatives.
Investigators have to decide whether they will deter- for an estimation of prevalence in a population of new-
borns. In the case of incomplete penetrance, this estima-mine the frequency of the pathological phenotype or the
frequency of the morbid genotype. In the first design, tion should be corrected. Reduced survival as well as
competing causes of death, however, will produce anindex cases and symptomatic relatives are included. How-
ever, in late-onset disorders such as autosomal dominant underestimation. Similarly, heterozygote frequency in a
dominant condition may be considered the equivalentdiseases, many heterozygotes will be symptomless for a
part of their lives. As a result, only a proportion will be of those having the morbid genotype at birth and who
are expected to be affected in the future.recognized as affected even though most will develop
the disease. Consequently, systematic screening may be Prevalence in small populations. Prevalence estimates
in small populations must be considered with caution.proposed to asymptomatic relatives. One may ask whether
it is ethical to use screening simply in order to classify They may not be representative of the common preva-
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lence values. It is well known that rare hereditary dis- AUTOSOMAL DOMINANT POLYCYSTIC
KIDNEY DISEASEeases, especially recessive, may occasionally be more
frequent in small populations (for example, Finns and Autosomal dominant polycystic kidney disease is charac-
French Canadians) than elsewhere. In some cases, gene- terized by progressive renal cyst formation and expansion
alogical studies suggested that the mutation might have leading to ESRD. Other manifestations include the pres-
been introduced by a small group of related individuals ence of cysts in other organs (liver, pancreas), heart valve
splitting off from existing populations (founder effect) defects, and an increased frequency of intracranial aneu-
[12]. Conversely, diseases that are otherwise relatively rysms. Two different loci are known to cause ADPKD,
common may be rare, even absent, or about as frequent PKD1, and PKD2. There is still an unmapped locus. In
in these small populations. European families, linkage studies have estimated that
PKD1 accounts for 86% of the disease and PKD2 for
most of the remaining cases [13]. The proportion ofMUTATION RATES
PKD1 families appears almost identical in Japan [14].
Many mutations reduce the life span or reduce the Autosomal dominant polycystic kidney disease is con-
ability of the person to reproduce or interfere with both. sidered the most common single-gene disorder that re-
Thus, a mutation with a deleterious effect on the pheno- sults in renal failure. ADPKD represented 2.6 and 2.9%
type tends to be selected against. The term “mutation of all incident cases of treated ESRD during the years
rate” refers to “the probability with which a particular 1992 to 1996 in the United States [15] and during the
mutational event takes place in a fertilized germ cell per years 1986 to 1994 in Japan, respectively [16]. If we
generation” [12]. It is necessary to study disorders that consider that ADPKD represents the near totality of
occur relatively frequently to find a sufficient number of patients classified as having “cystic kidney diseases” in
cases to provide the basis for a reasonable estimate. the United States, the adjusted incidence rate of ESRD
Underascertainment of affected individuals leads to un- patients with ADPKD was approximately 7 per million
derestimation of mutation rate. population per year (for the year 1996) and the adjusted
Only applicable to autosomal dominant traits, direct point prevalence approximately 50 per million popula-
calculation of the mutation rate can be made after evalu- tion (on December 31, 1996) [15]. Distribution was not
ation of the family history and verification that the dis- uniform among all ethnic groups; however, 3.4% of the
ease was not present in either parent [1]. Classically, the ESRD patients were Caucasian, 2.0% Asian, 1.2% Na-
mutation rate m is given by the number of children born tive American, and 1.1% African American. In Japan,
with a given genetic disease whose parents do not trans- the incidence of ESRD patients with ADPKD was 4.8
mit the disease divided by 2 N, N being the number of per million population per year (for the year 1995) [16].
live births during the study period, and the division by However, many patients never reach ESRD, and many
2 being necessary because the number of gametes is reach it only late in life. Although case inclusion differed,
double the number of individuals. However, most domi- two studies on age-related ESRD carried out in Canada
nant diseases are not discovered at birth, and only preva- [17] and in France [18] showed that prognosis was much
lence data obtained later in life are available. Estimation better than the previous clinical reports suggested. To
of mutation rate will, of course, depend on survival of avoid an ascertainment bias, Canadian authors excluded
affected individuals. index cases and based their analysis on family members
The indirect approach may be applied to various with cysts on ultrasonography. They showed that 25%
modes of inheritance, and formulas have been derived had ESRD by the age of 47 years, 50% by the age of
for each mode [1]. The principle is that there is a genetic 59, and 75% by the age 70. The French authors, who
equilibrium between mutation and selection in human included both probands and relatives with positive ultra-
populations. Selection can be measured in terms of fit- sonography, concluded that 22% had reached ESRD by
ness, symbolized as f, where f 5 1 implies no impairment the age of 50 years, 42% by the age of 58, and 72% by
in fertility relative to the general population, and f 5 0 the age of 73 years. Neither of these studies showed any
corresponds to complete infertility. In autosomal domi- difference between males and females. In contrast, the
Japanese survey showed a significant difference in meannant diseases, the formula is m 5
1
2
(1 2 f )p, where p is
age at initiation of dialysis between females (54.5 6 10.7
the birth prevalence. A useful approximation for f can years) and males (52.3 6 11.7) [14].
be obtained by comparing reproduction of patients with Phenotypic variability between families and within
that of their unaffected sibs. Another way is to determine families is obvious. Some of the variability between fami-
the number of children in a random age group of the lies is due to the gene. Compared with PKD1 patients
population with follow-up to the end of their reproduc- in a multicenter analysis, PKD2 patients presented with
symptoms later in life, lived longer, had a lower risk oftive period in comparison with patients.
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progressing to renal failure, and had fewer complica-
tions. The median age at death or ESRD was 53.0 years
(95% CI, 51.2 to 54.8) in individuals with PKD1 and 69.1
years (95% CI, 66.9 to 71.3) in those with PKD2 [19].
Consequently, with PKD2 being a less severe disease,
its relative frequency may be underestimated.
After the 1956 landmark study in Denmark by Dal-
gaard [20], which was the sole source of data on “fre-
quency” over a large number of years, surveys were con-
ducted in the United States [21], the United Kingdom [22],
France [23], the Seychelles [24], and Japan [16]. These
studies, carried out at different periods, largely differed
in criteria for ADPKD diagnosis, sources of ascertain-
ment, and case inclusion. It should be noted that in all,
missing patients, especially those with less severe disease
(probably the PKD2 patients) and a possible failure to
detect isolated cases, may be causes of incomplete ascer-
tainment. They also differed in the choice of epidemio-
logic measure since prevalence was estimated in the four
last studies [16, 22–24], but it was risk that was evaluated
in Denmark [20], whereas both incidence rates [21] and
risk [25] were evaluated in the United States.
Estimation of risk
Dalgaard’s estimation of risk is invariably quoted as
an estimation of prevalence in the general population.
In fact, as previously mentioned, such a risk allows the
estimation of birth prevalence of heterozygotes [4]. Nev-
ertheless, the use of Dalgaard’s risk as ADPKD birth
prevalence, without considering the competing causes of
death in the first part of the 20th century and the possibil-
ity of ADPKD being undiagnosed, should be considered
with caution.
Judging that a certain number of cases might not be
diagnosed, Dalgaard chose to estimate “the risk of being
ill from a certain disease during the course of one’s life”
[20]. He established a list for all “fresh” cases of typical
bilateral polycystic kidneys that appeared in Copenha-
gen during the periods 1920 to 1935 and 1935 to 1953
(Table 2). Only probands were included in the calcula-
tion. Their number diagnosed in each age group (15 to
19, 20 to 24, 25 to 29, . . . 75 to 79 years) was compared
with population figures, according to age and sex. The
five-year incidences, that is, the number of cases arising
per 100,000 of the general population in the course of
five years, were calculated. Summing incidences in each
sex led to establishment of risk curves. That curves for
the period prior to 1935 were below those after 1935 was
explained by improvement in social conditions leading to
an increase in hospital admissions and improved diagnos-
tic methods. From data obtained in the period 1935
through 1953, Dalgaard concluded the following: “The
actual risk of having polycystic disease of the kidneys
before the age of 80 is estimated as being hardly 1 per
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thousand. This estimation is a minimum figure, and must
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be regarded as an approximation.” There was no signifi-
cant difference between females and males.
A different study was conducted in Olmsted County
in order to estimate incidence rates in the years 1935 to
1980 (Table 3). [21] The survey was based on the Roches-
ter Epidemiology Program Project that supports popula-
tion-based studies of disease unique in the United States,
if not in the world [26]. Olmsted County is isolated from
other urban centers, the population relatively stable, and
medical records combining inpatient and outpatient data
assured the identification of almost all local residents in
whom a given disorder has been diagnosed. During the
period studied, more than 50% of all deaths were autop-
sied. According to the mode of diagnosis, three incidence
rates were defined. The calculation of rate A was based
on the number of symptomatic cases diagnosed during
life as well as those detected during family screening.
For the calculation of rate B, the authors added the
patients in whom diagnosis was made at autopsy. Inci-
dence rate C included an additional number of cases
that would have been found if all deaths of Olmsted
County residents had been autopsied. Comparing rates
A and C, the authors suggested that only about half of
the patients were clinically diagnosed during life. Using
these data, Torres, Holley, and Offord were able to calcu-
late the morbid risk [25]. By the age of 80, the minimum
risk (based on data used in calculation of rate A) was
approximately 1 per 1000, and the maximum risk (based
on data used for calculation of rate C) increased to 2.5
per 1000 (Table 2). As compared with curves for the
Copenhagen population, the Olmsted County curves in-
dicated an earlier diagnosis of the disease.
Morbid genotype prevalence
Although their sources of ascertainment differed, two
surveys, one carried out in South and Mid-Wales in the
United Kingdom [22] and the second in a French region,
the department of Cotes d’Armor in Brittany [23], were
both conducted to measure the prevalence of symptom-
atic and asymptomatic heterozygotes (Table 3). In Wales,
heterozygote frequency was 41 per 100,000 (or 1 per
2459), 2.8 times the pathologic phenotype prevalence.
In Brittany, heterozygote frequency was 90 per 100,000
(or 1 per 1111), 2.2 times the pathologic phenotype prev-
alence. On the one hand, both evaluations using crude
prior risk resulted in an overestimation of the number
of heterozygotes. On the other hand, ascertainment was
unlikely to be complete. The French study was single
hospital based. In contrast, in Wales, index patients were
ascertained through a register, but most presented with
renal failure. Families with a benign prognosis may have
been missed.
Pathologic phenotype prevalence
Prevalence was estimated in the Seychelles, an island
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in the Indian Ocean, where 65% of the population is of
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African descent and 30% of Caucasian or mixed descent of view. There is considerable variability in the degree
of involvement of the kidney and liver, with a clinical[24] (Table 4). The study included not only index cases,
but also asymptomatic relatives found to have cysts on spectrum ranging from infants not surviving the first
months of life to mildly affected adults. Although ex-ultrasonography. Not all accepted screening, thus lead-
ing to a possible underascertainment. All patients but tremely high in a Finnish study, the proportion of the
lethal neonatal form is not known [27]. It should beone were Caucasian, so that the prevalence in the African
and Caucasian populations were 2 and 184 per 100,000 noted that ARPKD does not belong to the group of
recessive diseases over-represented in Finland. There is,(or 1 per 544), respectively, increasing to 6 and 236 per
100,000 in the 25 to 39 age group. According to the however, no evidence of genetic heterogeneity. Outcome
of patients who survive the first month of life is variable,authors, a race differential detection of ADPKD is un-
likely since access to medical care is available and free but has become better than previously reported. Life-
table analysis reveals an actuarial renal survival of 86%of charge to all inhabitants. The high prevalence in the
Caucasian population suggested a founder effect. It was at one year and of 67% at 15 years [28]. ARPKD ac-
counted for 1.5% of children who started RRT beforehypothesized that the ADPKD gene(s) might have been
introduced to the island by one or more Caucasian indi- the age of 15 years between 1987 and 1991 in Europe
[29], and for 0.6% of incident cases of treated ESRDviduals among the few initial settlers and was conserved
in the Caucasian community, as interracial marriage was before the age of 20 in the United States in the years
1992 to 1996 [30]. The distribution among different eth-long uncommon.
The nationwide Japanese survey was conducted differ- nic groups is not known, but there were no black
ARPKD patients in the ESRD registry in the Unitedently [16]. Using the 1994 data obtained in departments
of nephrology randomly selected by a stratified sampling States.
The prevalence of the disease remains unknown. Themethod from all hospitals, the number of ADPKD pa-
lack of surveys is explained by the confused terminologytients without renal replacement therapy (RRT) was esti-
of cystic abnormalities, the highly variable clinical spec-mated to be 10,000 (CI 8200 to 11,900). Adding the 4594
trum, and the difficulties in differentiating ARPKD andpatients on dialysis gave a prevalence of 11.7 (CI 10.2
ADPKD in children [27]. The estimate of birth preva-to 13.2) per 100,000. Prevalence increased with age,
lence that is widely used was given in 1984 by Zerres,reaching 26.1 per 100,000 in the 55 to 59 years age group.
Vo¨lpel, and Weiss [31]. Combining data from the UnitedThe authors, assuming that there were patients not yet
States provided by Potter [32] in 1972, from the Hungar-diagnosed, adopted this high prevalence as that of pa-
ian Congenital Malformation Register for the years 1970tients below 55 years and consequently estimated the
through 1976 [33], and from the pediatric autopsy files oftotal number of ADPKD individuals to 31,000. This gave
the Children’s Hospital, University of Helsinki (Finland)a prevalence of 25 per 100,000 (or 1 to 4033). This ap-
for the years 1974 through 1978 [34], they noted theproach, based only on patients who were seen in Japa-
following: “Potter (1972) observed two cases born in thenese hospitals during a single year, likely underestimates
Chicago Lying-Hospital during a period in which therethe true prevalence of ADPKD in Japan.
were about 110,000 live births. The prevalence of cystic
Mutation rates kidneys (type I and II) [note: type I ARPKD; type II
renal dysplasia] was 0.11/1000 total births in HungaryThe only study on mutation rate in ADPKD was pro-
vided by Dalgaard, who judged it necessary to rely on between 1972 and 1976 [Rutkai and Czeizel 1982]. Mir
et al (1983) found about 50% type II and about 10%an indirect method [20]. Fitness was estimated at 0.77
to 0.87 by comparing the number of births in Copenha- type I kidneys among their renal cysts in pediatric autopsy
material. Combined data correspond with Potter’s obser-gen and the number of children born to patients, while
taking into account age at death and the year of birth. vation. Because of milder manifestations of type I kidneys
an overall incidence of about 1:40,000 may be a usefulThe mutation rate was 6.5 to 12 3 1025 per gene per
generation. Specific surveys are now needed to assess the rough estimate.” More recently, rectifying their conclu-
sion, they estimated that a birth prevalence of 0.5 permutation rate corresponding to each of the implicated
PKD1 and PKD2 genes. 10,000 live births (1 out of 20,000) should be used [35].
ALPORT SYNDROMEAUTOSOMAL RECESSIVE POLYCYSTIC
KIDNEY DISEASE Alport syndrome (AS) is characterized by hematuria
and progressive renal failure, associated with sensorineu-In ARPKD, the histologic changes are specific with
dilated collecting ducts and dysgenesis of the portal triad. ral hearing loss, sometimes ocular anomalies (anterior
lenticonus and perimacular flecks), rarely with leiomyo-Contrasting with this clear-cut anatomical definition, the
disease remains difficult to define from a clinical point matosis of the esophagus and tracheobronchial tree. Ul-
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trastructural alterations of the glomerular basement plasia of the elbows), and extraosseous abnormalities,
membrane are characteristic. AS, now understood as including nephropathy and glaucoma. Interfamily or in-
a consequence of structural abnormalities in type IV trafamily heterogeneity is remarkable, complicating the
collagen, the major component of basement membranes, identification of mildly affected individuals. There is, how-
is genetically heterogeneous. In 85% of the families, the ever, no evidence of genetic heterogeneity. NPS has been
disease is transmitted in an X-linked dominant pattern. described mainly in Caucasians, but also in Asians, in
Hematuria generally occurs at an average of 3.5 years patients from India and the middle East. Only a few
in affected males. ESRD develops in all affected males were Africans [40].
and more rarely in affected females. The rate of progres- Renal involvement represents the most serious com-
sion of renal failure shows interfamily variability, that plication. From combined data of the literature, it ap-
is, families in which the mean age at ESRD in males is pears that glomerular abnormalities (proteinuria) were
less than or greater than age 30. Conversely, in 15% of present in 62% of the cases and that 15% of the patients
the families, the disease is transmitted as an autosomal developed ESRD [40]. However, clinical renal involve-
recessive trait. Both young males and females progress ment is neither found in all affected families nor in all
to ESRD. affected members within families. The presence of colla-
In Europe, AS accounted for 1.5% of children who gen fibrils within the glomerular basement membrane
started RRT [29]. In the 1996 U.S. Renal Data System is considered pathognomonic and may be detected in
report, AS represented 0.3% (0.4% male and 0.2% fe- patients without proteinuria. This finding highlights the
male) of the incident cases of treated ESRD for the years probable underestimation of renal involvement when
1989 through 1993 [36]. The great majority of patients renal biopsy is not done.
were under 20 years of age. Most were white, but black, In the absence of epidemiologic surveys, the estimate
Asian, and Native American patients were reported. of prevalence currently used was given by Renwick and
The long-lasting controversy and confusion over the Izatt in 1965 [41]. They noted the following: “There are
identification of AS patients were due to imprecise diag- approximately 255 living patients with the nail-patella syn-
nostic criteria, wide phenotypic expression, and different drome known to us in the United Kingdom, which in the
modes of transmission. The estimation of prevalence
relevant years, 1954-1963, had a mean population size of
commonly used was based on clinical experience, not on
about 52 million. The count of living affected members
an epidemiologic survey. Following the observation of
was made in a particular way for each pedigree and thea large Utah kindred, Hasstedt and Atkin wrote the
fact that this was not the same year for each pedigreefollowing: “The disease frequency was fixed at 1/5000 for
produces confusion only in so far as the total nationalall analyses. This number was a rough estimate of our
population has increased slightly over the ten-year period.observation of about 300 known cases in Utah and south-
We can therefore confidently state that the prevalence ofern Idaho, with a population of about 1.5 million” [37].
the syndrome is more than 5 per million.” Because of theThey subsequently considered that it was the unusual
possibility of double ascertainment, the authors modifiedextent of the studies, and not a founder effect, that could
this estimate: “Thus, a prevalence figure of five per millionexplain this high frequency [38].
can be regarded as very much a lower limit and the true
figure is estimated to be about 22 per million, by the ratherBirth prevalence
crude approach of fitting a Poisson distribution to theFrom familial data on index patients diagnosed as hav-
number of pedigrees ascertained twice (2) and once (18)ing AS in Finland in the years 1990 through 1994, Finnish
in order to make a rough estimate of the number of U.K.authors estimated that birth prevalence should be 0.2 per
pedigrees not ascertained at all.”10,000 live births (1 out of 53,000; Table 5) [39]. Prevalence
in males was not given. As mentioned by the authors, not
all families were compatible with X-linked inheritance. CONGENITAL NEPHROTIC SYNDROME OF
Family studies were not complete. Index patients may THE FINNISH TYPE
have been missed, and material was biased toward the
Since the 1950s, congenital nephrosis has raised activemore severely affected, since heterozygous females with
interest among Finnish pediatricians because it has provedmild disease in the pedigrees may have been missed.
to be exceptionally common in Finns and very rare else-
where. Attention was focused on a particular group of
NAIL-PATELLA SYNDROME neonates and infants who had progressive edema and
massive proteinuria, showed no response to the standardNail-patella syndrome (NPS), or hereditary osteo-ony-
treatment of nephrotic syndrome, and died early, mostcho dysplasia, is an autosomal dominant disorder defined
of them by the age of two years. The only life-savingby the association of nail dysplasia, bone abnormalities
(absent or hypoplastic patellae, exostoses of the ilia, dys- treatment is conservative management and renal trans-
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plantation at the age of one or two years following bilat- JUVENILE NEPHRONOPHTISIS
eral nephrectomy. Juvenile nephronophtisis (NPH1) is an autosomal re-
About 30 single-gene diseases, most autosomal reces- cessive tubulointerstitial nephritis that is characterized
sive, have been found to be particularly frequent in the by progressive insidious polyuria caused by reduced uri-
Finnish population and were termed “Finnish Heritage nary concentrating ability preceding an ineluctable de-
of Disease” [42]. The first to be recognized was CNF. The cline in renal function. ESRD usually occurs around
puberty. Great confusion exists in the literature regard-small number of original ancestors, the location between
ing the definition and characteristics of the disease. ThisRussia and Sweden with differing heritage and language,
results from: (1) the absence of clinical, biological, andthe geographic factors acting as barriers and favoring
histologic criteria, although the extreme thickening ofgenetic isolates, the low increase of the population, and
the tubular basement membrane with a “tyre-like” ap-the continuing isolation of groups of settlers characterize
pearance seems for some pathologists characteristic ofFinland. The high prevalence of autosomal recessive dis-
the disease by its severity and diffusion; (2) the clinicaleases is due to the chance inclusion or occurrence of one
heterogeneity caused by the number of extrarenal abnor-mutation in the small founding population, followed by
malities described as associated with NPH1, such as ta-enrichment through genetic drift in the population that
peto-retinal degeneration with flat electroretinogramexpanded while isolated [43]. CNF is not unique to the
(Leber amaurosis) present in 10 to 15% of the patientsFinnish population. Most other cases were reported among
and constituting the Senior–Løken syndrome, cerebellar
Caucasians, but also among blacks, Japanese, American
ataxia, liver fibrosis, and cone-shaped epiphyses; and
Indians, Tunisians, and Maoris. The same gene seems (3) the clinical and morphological resemblance to an
to be affected in Finnish and non-Finnish families. Muta- autosomal dominant form named medullary cystic dis-
tions of the NPHS1 gene have been observed in non- ease (ADMCKD), differing from recessive NPH1 by its
Finnish patients from Europe, North America, and North mode of inheritance, its clinical course with development
Africa [44]. of ESRD mainly in adults, and the lack of extrarenal
associations.
Birth prevalence NPH1 is genetically heterogeneous. In Europe, the
Since the disease was first defined in Finland, a list NPHP1 gene is responsible for approximately 85% of
of all cases has been kept in Helsinki. In 1965, Norio the affected families. In more than 70% of these families,
NPHP1 is at least partly deleted. NPH1 patients with andestimated birth prevalence to 1 per 10,000 live births and
without the deletion do not show significant difference ininsisted on the variations in prevalence among different
the rate of progression to ESRD [48]. There is, however,Finnish regions [42]. In the 1976 nationwide survey [45],
a subset of families, especially the families with Senior-birth prevalence was estimated at 1.2 per 10,000 live births
Løken syndrome, who do not show linkage with NPHP1.(or 1 out of 8200; Table 5). Since some infants might die
Finally, ADPCKD has been shown to be geneticallyduring the first days of life without CNF having been
different from NPH1 and genetically heterogeneous [49].diagnosed, birth prevalence may be underestimated. In
NPH1 has been mainly reported in Europe and NorthEast Finland where prevalence was known to be high,
America. In Europe, the “ADMCKD/NPH1 complex,”prenatal screening (based on a high afetoprotein concen-
the most frequent genetic cause of chronic renal failuretration in amniotic fluid) was offered to women [46]. If
in childhood, accounted for 4.7% of children who startedall births had occurred, the birth prevalence would have
RRT [29]. In the United States, ADMCKD/NPH1 and
been 4.2 per 10,000 live births. As a result of the screening
cystinosis were equally frequent in the pediatric treated
and pregnancy termination, it fell to 0.9 per 10,000 live ESRD population, representing each 0.7% of incident
births. cases for the years 1992 to 1996 [30]. Cases have been
CNF was found to be frequent in a subgroup of the Old reported in Japan, South America, and Israel, as well as
Order Mennonites known as the Groffdale (the more in children of Arab, Turkish, and Indian origin. Within
conservative group) [47]. Ancestors immigrated from the pediatric ESRD population in the United States,
Switzerland during the 18th century to Lancaster County, there were, however, no black patients with ADMCKD/
Pennsylvania, USA, and no explicit Finnish ancestry is NPH1.
known. Birth prevalence was estimated to be 2 per 10,000
Birth prevalencelive births during the period 1985 to 1994, 20 times
greater than that observed in Finland. Genetic analysis Until recently, there were no reliable figures concern-
showed that mutation of the NPHS1 gene is most likely ing prevalence. The Finnish survey reflects the difficulties
of recent origin, uncovered by inbreeding and amplified in distinguishing between the recessive and the dominant
forms [50]. Using familial data on index patients diag-by genetic drift.
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nosed as having the recessive form of NPH1, Finnish Pathologic phenotype prevalence and birth prevalence
authors estimated that birth prevalence for the years Two surveys, mostly based on patients ascertained
1963 to 1982 should be 0.13 per 10,000 live births (1 out because of visual impairment, allowed an estimation of
of 80,000; Table 5). According to the authors, underas- prevalence (Table 4). In the landmark study by Amman
certainment is likely since adult patients as well patients in Switzerland, 57 cases belonging to 26 pedigrees were
not yet having presented typical signs of NPH1 may have registered [54]. Most patients were ascertained through a
been missed. As usual in Finland, a study was undertaken register for tapeto-retinal degeneration. Prevalence was
to evaluate whether NPH1 deletion originated from com- estimated to 0.6 per 100,000. As mentioned by the au-
thor, the geographic distribution of the syndrome wasmon founders. The founder effect was excluded by hap-
not ubiquitous, but was grouped into five distinct regions.lotype analysis [51].
Interestingly, 22 of the 57 cases (belonging to 2 pedi-
grees) were concentrated in central Switzerland, thus
BARDET-BIEDL SYNDROME suggesting the isolated character of the region. Preva-
lence reached 5.7 per 100,000 in Newfoundland [55]. InBardet-Biedl syndrome (BBS) is an autosomal reces-
that island, many small communities were founded by asive disorder, genetically heterogeneous, with currently
few families originally from the same part of the Westfive gene loci. The contribution of each of these loci to
country of England or Ireland [56]. Contact betweenthe development of the disease appears to depend on
communities was, until recently, by sea and was impossi-ethnic background, BBS1 most commonly occurring in
ble for several months of the year, and consanguinitywhite families [52]. Cardinal manifestations classically
was likely to be high in certain parts of the island. How-include postaxial polydactyly, rod cone dystrophy (lead-
ever, the scattered distribution of families, as well as theing rapidly to blindness), obesity, male hypogenitalism,
identification of three distinct BBS subtypes, was not
and mental retardation. The phenotypic expression of
consistent with an expectation of a single founder effect.
the disease displays not only interfamilial but also intra- Recently, a founder effect was demonstrated for a group
familial variation. As shown by the results of a large of BBS1 families coming from the same part of the island
survey of patients identified through the Laurence-Moon- [56]. In the mixed Arab population of Kuwait, also char-
Bardet-Biedl Society of Great Britain and through the acterized by a high consanguinity rate, prevalence was
Guy’s hospital Bardet-Biedl Register in the United King- found to be 2.8 per 100,000, but a complete registry
dom, the clinical variability and the slow development was not available [57]. Furthermore, two thirds of the
of the clinical features as well as overlapping phenotype patients were Bedouins who constitute an almost isolated
observed in Laurence-Moon subjects render difficult the population with a multigenerational practice of consan-
identification of the patients at a young age [53]. guineous marriages. The prevalence among Bedouins
Renal abnormalities (persistent fetal lobulation, caly- reached 7.4 per 100,000, and birth prevalence was esti-
ceal clubbing and blunting, cysts or diverticula, scarring, mated to 1.4 per 10,000 live births [58]. BBS was also
dysplastic kidneys) are particularly common and are reported to be frequent among Palestinian Arab families
living in Israel [59].even regarded by some as a cardinal feature. Chronic
renal failure, sometimes beginning in early childhood, is
now reported to be the major cause of early morbidity NEPHROPATHIC CYSTINOSIS
and mortality. Because of the limited renal investigations
Nephropathic cystinosis, an autosomal recessive disor-usually performed in BBS patients, renal abnormalities
der, was first thought to affect only the kidney. Withand renal impairment are, however, diagnosed in rela-
RRT, the disorder appeared multivisceral, with other
tively few cases. For example, only 52% of the patients
organ involvement developing with time. These include
identified in the United Kingdom study had undergone not only ocular complications (corneal cystine deposition
any radiological investigation of the renal tract [52]. Of and retinopathy leading to visual impairment), but also
these, 46% were found to have renal abnormalities. Five thyroid, gonad, and endocrine pancreas deficiency, the
percent had chronic renal failure, and 4% were trans- possibility of liver and spleen involvement, and finally the
planted. In contrast, the prospective cohort study carried risk of muscle and central nervous system complications.
out in Newfoundland (Canada) included a complete The primary defect is a lysosomal cystine transporter
evaluation of the renal function in all patients [53]. Renal deficiency provoking lysosomal cystine storage. It leads
impairment occurred in 25%, with nearly half of them to proximal tubular defect, rickets, and growth retarda-
having progressed to ESRD. Ultrasound of the kidneys, tion in the first year of life, followed by glomerular im-
performed in 81% of the patients (most having serial pairment progressing to ESRD at approximately 10 years
studies), disclosed the presence of structural renal abnor- of age. A French epidemiologic study showed that chronic
renal insufficiency occurred at 6.2 6 3.5 years of age andmalities in 96% of them.
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RRT started at 9.8 6 2.4 years [60]. It is speculated that all neonates by the Neonatal Screening Laboratory in
Birmingham for the years 1981 to 1991, was approxi-early and life-long cysteamine therapy will delay the age
mately 10 times higher in Pakistanis (1 out of 3613; CIof renal failure.
1 out of 1834 to 1 out of 8378) than among NorthwestIn Europe, cystinosis is the second cause of ESRD in
Europeans (1 out of 46,564; CI 1 out of 27,230 to 1 outchildren, after NPH1. It accounted for 3.5% of children
of 87,476) [69]. Such a significant difference, not specificwho started RRT between 1987 and 1991 [29]. In the
to cystinosis, but common to several other inborn errorsUnited States, ADMCKD/NPH1 and cystinosis were
of metabolism, was interpreted as due to consanguinityequally common in the pediatric ESRD population. For
in the Pakistani population. Children, however, maythe years 1992 to 1996, they represented each 0.7% of
have died without recognition of cystinosis. Similarly,incident cases of treated ESRD [30]. In French Canada,
most cases reported in Israel were noted in North Afri-cystinosis constituted one of the most common causes
cans, a genetically isolated population and in which mar-of ESRD in children. A survey of Canadian pediatric
riages between relatives were frequent [70].nephrology centers found that 60% of the patients with
cystinosis were from Quebec, and of these, the majority
were French Canadians [61]. This finding was initially PRIMARY HYPEROXALURIA TYPE I
interpreted as consistent with a founder effect caused
In primary hyperoxaluria type I (PH1), a recessiveby the small number of carrier individuals who were
autosomal disease, the elevated urinary oxalate excre-present in the founding population of Quebec. Molecular
tion is due to deficiency of liver-specific peroxisomalanalysis, however, revealed that there are several found-
alanine:glyoxylate aminotransferase. The excessive pro-ing cystinosis mutations with origins both in France and
duction of oxalate leads to recurrent urolithiasis, nephro-in Ireland, with the Irish mutation having made the most
calcinosis, progressive renal insufficiency, and then tosignificant contribution to the French Canada population
oxalosis, meaning extrarenal (bone, muscle, artery, eye,[62]. Conversely, cystinosis is one of the recessive dis-
skin, nerve, heart, etc.) oxalate accumulation. The clini-
eases never diagnosed in Finland [43]. Although cys-
cal spectrum is wide, and patients are seen at all ages.
tinosis is considered a disorder of fair-skinned individu-
At one extreme, patients present with the most severe
als of European descent, the disease does occur in blacks, acute neonatal form and at the other extreme they may
Hispanics, Indians, Pakistanis, and persons of Middle remain asymptomatic until middle age. The survey car-
Eastern descent [63]. In the United States, however, ried out in Switzerland showed that by the age of 15
92.3% of ESRD children were white, and there were no years, 20% of patients were in ESRD and 10% had died
black patients [30]. and that at 25 years, 50% were in ESRD and 20% had
died [71]. In Europe, oxalosis accounted for 1.6% ofBirth prevalence
children who started RRT before the age of 15 years
Birth prevalences of 0.06 [60], 0.03 [64], 0.06 [66], 0.09 between 1987 and 1991 [29]. In ethnic groups with con-
[67] per 10,000 live births have been estimated in the sanguinity such as in Tunisia, PH1 accounted for 18%
various surveys conducted in Europe (France, West Ger- of children with ESRD, which is 10 times higher than in
many, and Denmark; Table 5). All authors claimed that Europe [72].
ascertainment was nearly complete, but some children The estimation of prevalence in the pediatric popula-
may have died without recognition of the underlying diag- tion provided by Latta and Brodehl [73] in 1990 was
nosis. Similar values were reported in Australia, where based on German data on ESRD. They noted the follow-
birth prevalence was evaluated through two laboratories ing: “In the registry of the European Dialysis and Trans-
performing all enzymatic analyses for lysosomal storage plantation Association about 1% of children developing
disorders in the country (National Referral Laboratory ESRD every year account for primary hyperoxaluria
in Adelaide and Division of Chemical Pathology in Bris- among those developing ESRD. Our data show 2%–2.7%
bane) [65]. It was 0.04 (1 out of 281,000) for the years of children with hyperoxaluria among those developing
1980 to 1996 in a population predominantly of British ESRD. These data are comparable to those of the Arbeits-
extraction. If all births had occurred (that is, in the ab- gemeinschaft fu¨r Pa¨diatrische Nephrologie for 1979–
sence of screening and pregnancy termination), the birth 1982. Assuming five to six children developing ESRD
prevalence would have been 0.05 per 10,000 live births per million children and year, the incidence of primary
(1 out of 192,000). The reasons for the higher prevalence hyperoxaluria can be assumed to be of 1 in 5–15,000,000
noted in a French region, Brittany, are obscure. children between 0 and 15 years. This figure probably
Birth prevalence was higher (1 out of 6237) in the underestimates the true incidence of the disease.”
Saguenay-Lac-St-Jean, a geographically isolated region
Pathologic phenotype prevalence and birth prevalencelocated in Northeastern Quebec [68]. In an ethnically
diverse society such as that existing in the West Midlands The surveys conducted in Switzerland [71] and France
[74] showed the rarity of the disease, although prevalenceof the United Kingdom, birth prevalence, evaluated in
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in the Swiss survey (0.26 per 100,000) was twice that TUBEROUS SCLEROSIS
in the French survey (0.11 per 100,000) in the whole Tuberous sclerosis (TSC) is a dominantly inherited
population (Table 4). It reached 0.19 in the 0- to 15-year syndrome characterized by the development of hamarto-
age group in France. Neither of the studies, however, mas in many tissues and organs, such as skin, brain, heart,
had consulted urologists, and prevalence may have been kidney, eyes, and the skeleton. Their number, size, and
underestimated. Birth prevalence, evaluated in neonates localization show high variability, and severity can vary
greatly within the same family. TSC exhibits locus heter-through the Neonatal Screening Laboratory at Birming-
ogeneity with two genes, TSC1 and TSC2, the TSC2 andham, was approximately 10 times more frequent in Paki-
PKD1 genes lying adjacent to one another on chromo-stanis (1 out of 14,552; CI 1 out of 4001 to 1 out of 119,337)
some 16. Family-based linkage studies have indicatedthan among Northwest Europeans living in the West
that proportions of TSC due to the TSC1 and TSC2Midlands (1 out of 201,777; CI 1 out of 69,023 to 1 out
genes were approximately equal [77]. Mainly describedof 977,917) [69]. As for cystinosis, such a difference was
in Caucasian populations, TSC has also been reportedinterpreted as due to consanguinity in Pakistanis.
in black and Asian patients [78].
The kidney is frequently involved, with angiomyolipo-
mas, renal cysts, and more rarely cancers. A survey car-FABRY DISEASE
ried out in Germany and Switzerland showed that 48%Fabry disease, a recessive X-linked disorder, results
of the patients (newborns to 70 years) screened by ultra-
from deficient activity of the lysosomal enzyme a-galac-
sonography, computed tomography, or intravenous ur-
tosidase A. The defect leads to progressive accumulation ography had renal abnormalities (angiomyolipomas in
of glycosphingolipids throughout the body. Affected 28%, cysts in 30%, and carcinoma in 0.04%) [79]. No
males show angiokeratoma, acroparesthesia, corneal significant phenotypic differences have been discovered
opacity, and hypohydrosis in childhood. With age, they between TSC1 and TSC2 families, but severe early onset
develop disease of the kidneys, heart, and central ner- renal cystic disease is associated with deletion involving
vous system. In the kidney, accumulation of glycolipid both TSC2 and PKD1 [80]. Renal failure is related to
is noted early in life. Progressive renal failure occurs in nephronic reduction caused by tumor invasion or to sur-
the second to fourth decade of life. Generally, female gery for tumor or hemorrhage. If better management of
heterozygotes are asymptomatic. Rarely are they se- neurological disorders improves survival, renal involve-
verely affected. Most patients are Caucasian, but black, ment might be expected to become a more frequent com-
Hispanic, American Indian, Egyptian, and Asian cases plication. The prevalence of TSC with ESRD was evalu-
have also been observed [75]. ated at 0.07 per 100,000 in French dialysis centers [81].
The rarity of the disease, its late recognition, and the
Pathologic phenotype prevalencevariability in clinical features expressed in carrier fe-
Although the highly variable expression of the diseasemales are obstacles to epidemiologic surveys. As men-
renders the prevalence difficult to establish, TSC wastioned by Desnick (personal communication), “The 1 in
the early subject of a large number of epidemiologic40,000 is an estimate based on the frequency of Fabry
studies [82]. The progressive formulation of criteria hasdisease compared with other X-linked disorders. I believe
enabled better ascertainment in recent studies [83]. Asthat the disease may be more frequent due to the recent
the disease is the most common dominantly inheritedrecognition of the milder cardiac variant.”
condition causing epilepsy and mental handicap, various
authors made estimations of prevalence by studying onlyBirth prevalence
TSC in populations of institutionalized patients, thus
As for cystinosis, birth prevalence in the Australian missing individuals not affected by fits and mental retar-
population was evaluated through the results of the two dation. Because of their small number of patients, the
laboratories performing all enzymatic analyses for lyso- surveys carried out in Scotland [84] and the two succes-
somal storage diseases. It was estimated to 0.09 per sive studies in Olmsted County [85, 86] may not accu-
10,000 live births (1 out of 117,000) for the years 1980 rately reflect the prevalence. The surveys conducted in
to 1996 [67]. It may be higher since a less severe disease the United Kingdom provided approximately similar
may not have been diagnosed, especially in the adult prevalence values per 100,000, 2.9 within the Oxford
population. In the Netherlands, the records of the labora- region [87], 3.7 in the West of Scotland [82], and 3.9 in
tories of the clinical genetic centers involved in the post- the Wessex region [88, 89] (Table 4). Prevalence reached
natal and prenatal diagnosis led to an evaluation of birth 6.5 [87] and 8.3 [82] in the school-age group. A Japanese
prevalence to be 0.02 per 10,000 live births (or 0.04 for survey estimated prevalence at 3.2 per 100,000, close
to the British values [90]. The highest prevalence evermale births) in the years 1970 to 1986 [76].
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reported, 14.7 per 100,000 in the 11- to 15-year-old popu- findings by systematic screening, prevalence was esti-
mated at 2.57 per 100,000 through a single-hospital basedlation, was found in the western region of Sweden [91].
The authors were aware, however, that a number of study in Germany (Table 4) [93].
cases with late onset or mild symptoms had been missed
Morbid genotype prevalenceand concluded that because a number of patients may
escape recognition, TSC might be more common than Two surveys, differing by the sources of ascertainment
(multiple specialists vs. genetic register), but using thepreviously believed. In agreement with this hypothesis
are the results of a capture-recapture analysis carried out same mode of calculation, were carried out in the United
Kingdom (Table 3). Prevalence of heterozygotes wasin the Wessex region suggesting that, despite the efforts
of the investigators to locate all cases, more than half estimated at 1.19 [94] and 1.89 per 100,000 [95]. From
the prevalence data in the 25- to 49-year age group, inremain undetected [10]. Thus, the revised estimate of
prevalence, taking account of unascertained cases, in- which ascertainment of heterozygotes appeared likely to
be the most accurate, the authors suggested that birthcreased from 3.9 to 8.8 per 100,000 (95% CI, 6.8 to 12.4).
prevalence should be 0.22 [94] and 0.27 [95] per 10,000
Mutation rates live births.
As early as 1935, the high frequency of sporadic TSC
Mutation ratecases that could be considered as new mutations was
noted [12] with a frequency of 60 and 75% in the two As early as 1970, the mutation rate was estimated to
be 1.8 3 1027 [12]. Using their prevalence data, BritishBritish studies [82, 87], and 32% in the Japanese study
[90]. From these data, the authors directly estimated the authors evaluated mutation rate; direct estimations gave
4.4 3 1026 in one [94] and 1.4 3 1026 in the other studymutation rate at 2.5 3 1025 in the United Kingdom
[82, 87] and 1.6 3 1025 in Japan [90]. Calculation of the [95]. In addition, mutation rate was evaluated by indirect
estimation in the first study [94]. Fitness was estimatedmutation rate corresponding to each of the implicated
at 0.83 by comparing the number of children born togenes might be ideally possible by incorporating DNA
patients and their normal sibs. The mutation rate wasresults into the definition.
2.32 3 1025, within the 95% CI calculated by the direct
method.
VON HIPPEL-LINDAU DISEASE
Von Hippel-Lindau (VHL) disease, a dominantly in-
CONCLUSIONherited disorder, predisposes to a variety of benign and
The distribution of genetic diseases in human popula-malignant tumors. The most common are hemangioblas-
tions is a function of the combination of different forcestoma of the cerebellum, brain stem and spinal chord,
such as mutation rate and selection, migration, founderretinal angiomas, renal cysts and renal cell carcinoma,
effect and genetic drift, and mating patterns. Since mostpancreatic cysts, pheochromocytoma and epidymal cys-
epidemiologic surveys are subject to a certain amount oftadenomas. Phenotypic variability both between families
criticism, estimations of prevalence in populations shouldand within families is evident. Interfamilial differences
be considered with caution. They might, however, give anin predisposition to pheochromocytoma reflect the dif-
order of magnitude. A part of the variation found betweenferent forms of mutations in the VHL gene. Cumulative
populations may be due to methodological differencesage distribution curves seem to indicate that among pa-
in the procedure. Consequently, the mode of calculationtients who survive to 60 to 70 years of age, 90 to 95%
of prevalence, the definition of the disease and modesdevelop kidney lesions [92]. Cysts are rarely responsible
of diagnosis, the inclusion of the cases, the sources offor deterioration of renal function. When it does occur,
ascertainment, the period of time during which eventsrenal insufficiency is the result of renal surgery per-
were counted, and the determination of the size of theformed for renal cell carcinoma. Improvement in screen-
population have to be clearly compared. In addition, alling and treatment of hemangioblastoma of the cerebel-
causes of underascertainment should be analyzed.lum has now promoted renal carcinoma as the leading
Several aspects can remain problematic. Improvementcause of death.
in medical care and in treatment modalities over time
Pathologic phenotype prevalence may significantly alter survival and thereby enhance the
chance of diagnosis during life. Thus, an increase in prev-Von Hippel-Lindau disease has been regarded as a
rare disease. However, individuals presenting with only alence may be due to longer survival of patients with
renal failure, better ascertainment of the cases, or a com-one symptomatic lesion are not always carefully screened
for other manifestations, thus leading to an ignored diag- bination of these factors. Another point is that preva-
lence may vary with age. If two populations have a differ-nosis. Following inclusion of symptomatic patients as
well as first-degree relatives found to present abnormal ent age distribution, prevalence can differ even if the
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